ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

BACKGROUND: Many advanced hepatocellular carcinoma (HCC) patients are receiving sorafenib treatment. Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Gastrointest Oncol
Main Authors: Takaya, Hiroaki, Namisaki, Tadashi, Shimozato, Naotaka, Kaji, Kosuke, Kitade, Mitsuteru, Moriya, Kei, Sato, Shinya, Kawaratani, Hideto, Akahane, Takemi, Matsumoto, Masanori, Yoshiji, Hitoshi
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2019
Assuntos:
Observational Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522768/
https://ncbi.nlm.nih.gov/pubmed/31139312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v11.i5.424
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados